Literature DB >> 26861570

In vivo emergence of ceftaroline resistance during therapy for MRSA vertebral osteomyelitis.

Edgar H Sanchez1, Rodrigo E Mendes2, Helio S Sader2, Genève M Allison3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26861570      PMCID： PMC4867098          DOI： 10.1093/jac/dkw001

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  6 in total

1.  Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis.

Authors:  Cédric Jacqueline; Gilles Amador; Jocelyne Caillon; Virginie Le Mabecque; Eric Batard; Anne-Françoise Miègeville; Donald Biek; Yigong Ge; Gilles Potel; Antoine Hamel
Journal:  J Antimicrob Chemother       Date:  2010-06-08       Impact factor: 5.790

2.  How allosteric control of Staphylococcus aureus penicillin binding protein 2a enables methicillin resistance and physiological function.

Authors:  Lisandro H Otero; Alzoray Rojas-Altuve; Leticia I Llarrull; Cesar Carrasco-López; Malika Kumarasiri; Elena Lastochkin; Jennifer Fishovitz; Matthew Dawley; Dusan Hesek; Mijoon Lee; Jarrod W Johnson; Jed F Fisher; Mayland Chang; Shahriar Mobashery; Juan A Hermoso
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-01       Impact factor: 11.205

3.  Characterization of methicillin-resistant Staphylococcus aureus strains recovered from a phase IV clinical trial for linezolid versus vancomycin for treatment of nosocomial pneumonia.

Authors:  Rodrigo E Mendes; Lalitagauri M Deshpande; Davida S Smyth; Bo Shopsin; David J Farrell; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2012-09-12       Impact factor: 5.948

Review 4.  Ceftaroline fosamil: a new broad-spectrum cephalosporin.

Authors:  Joseph B Laudano
Journal:  J Antimicrob Chemother       Date:  2011-04       Impact factor: 5.790

5.  Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective.

Authors:  Richard A Alm; Robert E McLaughlin; Veronica N Kos; Helio S Sader; Joseph P Iaconis; Sushmita D Lahiri
Journal:  J Antimicrob Chemother       Date:  2014-04-28       Impact factor: 5.790

6.  Methicillin-resistant Staphylococcus aureus epidural abscess treated with ceftaroline fosamil salvage therapy.

Authors:  John Bucheit; Rebeccah Collins; Prajwol Joshi
Journal:  Am J Health Syst Pharm       Date:  2014-01-15       Impact factor: 2.637
  6 in total
  5 in total

Review 1.  Resistance to Non-glycopeptide Agents in Serious Staphylococcus aureus Infections.

Authors:  Kyle C Molina; Vanthida Huang
Journal:  Curr Infect Dis Rep       Date:  2016-12       Impact factor: 3.725

Review 2.  Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and its Application.

Authors:  Juwon Yim; Leah M Molloy; Jason G Newland
Journal:  Infect Dis Ther       Date:  2016-12-30

3.  Application of Next-Generation Sequencing for Characterization of Surveillance and Clinical Trial Isolates: Analysis of the Distribution of β-lactamase Resistance Genes and Lineage Background in the United States.

Authors:  Rodrigo E Mendes; Ronald N Jones; Leah N Woosley; Vincent Cattoir; Mariana Castanheira
Journal:  Open Forum Infect Dis       Date:  2019-03-15       Impact factor: 3.835

4.  Evaluation of in vitro activity of ceftaroline on methicillin resistant Staphylococcus aureus blood isolates from Iran.

Authors:  Negin Abdizadeh; Mehri Haeili; Hossein Samadi Kafil; Amin Ahmadi; Mohammad Mehdi Feizabadi
Journal:  Iran J Microbiol       Date:  2021-08

5.  Evaluation of the Revised Ceftaroline Disk Diffusion Breakpoints When Testing a Challenge Collection of Methicillin-Resistant Staphylococcus aureus Isolates.

Authors:  Helio S Sader; Paul R Rhomberg; Timothy B Doyle; Robert K Flamm; Rodrigo E Mendes
Journal:  J Clin Microbiol       Date:  2018-11-27       Impact factor: 5.948
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.